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INTRODUCTION
Rho GTPases represent a key family within the 
superfamily of Ras-related small G-proteins that plays 
fundamental roles in biology and disease. Among the 
members of this family, Rac GTPases (Rac1, 2, and 3) 
have been widely implicated in numerous cellular 
functions, including the regulation of actin cytoskeleton 
dynamics, cell motility, and the progression through 
the cell cycle. Rac GTPases cycle between a GDP-
bound inactive state and a GTP-bound active state that 
is responsible for activation of effectors. Rac activity 
is tightly regulated by guanine nucleotide exchange 
factors (Rac-GEFs), which activate Rac by promoting the 
exchange of GDP by GTP, and GTPase-activating proteins 
(GAPs) that accelerate Rac intrinsic GTPase activity, 
leading to its inactivation [1–3]. Dysregulation of the Rac 
pathway is a common event in human cancer and has been 
largely associated with metastasis in a number of cancer 
types. Although gain-of-function mutations in Rac and 
a constitutively active splice variant (Rac 1b) have been 
found in a number of cancer types [4–7], hyperactivation 
of Rac is for the most part associated with aberrant 
overexpression or hyperactivation of Rac-GEFs [8–11]. 
Functionally, Rac hyperactive status leads to enhanced 
activation of downstream effectors such as Pak1 and the 
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ABSTRACT
The Rac nucleotide Exchange Factor (Rac-GEF) P-Rex1 is highly expressed in 
breast cancer, specifically in the luminal subtype, and is an essential mediator of actin 
cytoskeleton reorganization and cell migratory responses induced by stimulation of 
ErbB and other tyrosine-kinase receptors. Heregulin (HRG), a growth factor highly 
expressed in mammary tumors, causes the activation of P-Rex1 and Rac1 in breast 
cancer cells via ErbB3, leading to a motile response. Since there is limited information 
about P-Rex1 downstream effectors, we carried out a microarray analysis to identify 
genes regulated by this Rac-GEF after stimulation of ErbB3 with HRG. In T-47D breast 
cancer cells, HRG treatment caused major changes in gene expression, including 
genes associated with motility, adhesion, invasiveness and metastasis. Silencing 
P-Rex1 expression from T-47D cells using RNAi altered the induction and repression 
of a subset of HRG-regulated genes, among them genes associated with extracellular 
matrix organization, migration, and chemotaxis. HRG induction of MMP10 (matrix 
metalloproteinase 10) was found to be highly sensitive both to P-Rex1 depletion and 
inhibition of Rac1 function by the GTPase Activating Protein (GAP) β2-chimaerin, 
suggesting the dependence of the P-Rex1/Rac1 pathway for the induction of genes 
critical for breast cancer invasiveness. Notably, there is a significant association in 
the expression of P-Rex1 and MMP10 in human luminal breast cancer, and their co-
expression is indicative of poor prognosis.
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consequent elevated migratory and invasive capacity of 
cancer cells, ultimately favoring metastatic dissemination 
[11–14].
In a previous study we identified P-Rex1 as a key 
Rac-GEF implicated in actin cytoskeleton reorganization 
and motility of breast cancer cells [15]. P-Rex1, which was 
originally discovered in neutrophils, is dually activated by 
the PI3K product PIP3 and Gbγ subunits upon stimulation 
of tyrosine-kinase and G-protein-coupled receptors 
[16–18]. Silencing the expression of P-Rex1 from breast 
cancer cells largely impairs the elevation in Rac-GTP 
levels in response to growth factors such as EGF (ErbB1/
EGFR ligand) and heregulin/neuregulin-1 (HRG, ErbB3/
ErbB4 ligand), drastically affecting the motile capacity 
of these cells [15, 19]. Interestingly, P-Rex1 is highly 
overexpressed in breast cancer cell lines, specifically 
in those of luminal origin. P-Rex1 overexpression only 
occurs in a subset of human breast cancers, namely 
luminal A and B subtypes, which may be the consequence 
of altered epigenetic regulatory mechanisms that result in 
demethylation of the PREX1 gene promoter [20]. P-Rex1 
up-regulation in breast cancer has been linked with a high 
probability of metastatic dissemination in patients [15].
Dysregulation of the expression of ErbB receptors 
and their ligands is a common feature in many human 
cancers. Hyperactivation of the pathways controlled 
by ErbB receptors leads to uncontrolled growth, 
transformation, and enhanced motility and invasion. EGFR 
mutations are indeed major drivers of cancer progression, 
and ErbB2 amplification is a common oncogenic event 
in breast cancer [21–23]. ErbB3 also plays important 
roles in cancer, as it dimerizes preferentially with ErbB2 
to confer an oncogenic signal [22, 24]. It has been 
reported that overexpression of HRG, which occurs in a 
significant fraction of mammary tumors, contributes to 
the tumorigenic and invasive capacities of breast cancer 
cells, even in the absence of ErbB2 overexpression 
[25, 26]. In support of the oncogenic role of HRG in 
breast cancer, transgenic overexpression of this growth 
factor in mouse mammary glands leads to the development 
of adenocarcinomas [27]. Notably, HRG regulates the 
expression of immediate early genes in estrogen receptor 
positive cells, including genes regulated by MAPK and 
the PI3K pathways, both established effectors of ErbB 
receptors [28]. The ErbB3 pathway has been implicated 
in the resistance to anticancer agents and is among the 
kinome pathways reprogrammed during drug resistance 
[22, 29, 30], thus highlighting the crucial need for 
dissecting downstream effectors of this receptor network.
Given the relevance of the P-Rex1/Rac1 pathway 
in breast cancer progression, and since the Rac pathway 
controls a number of key functions implicated in gene 
expression [31–33], we decided to pursue an analysis 
of genes regulated by P-Rex1 in breast cancer cells. 
As stimulation of ErbB3 by HRG causes a prominent 
activation of Rac1 in luminal breast cancer cells via 
P-Rex1, leading to a motile response, we investigated 
how silencing P-Rex1 could affect the regulation of gene 
expression by this growth factor. Our results identified a 
characteristic profile of P-Rex1-regulated genes in breast 
cancer cells, arguing for the involvement of the P-Rex1/
Rac1 pathway in the control of gene expression and breast 
cancer progression.
RESULTS
Gene expression changes induced by HRG in 
T-47D breast cancer cells
As a first step in our search for mechanisms by 
which P-Rex1 mediates HRG responses in breast cancer, 
we first set to explore global changes in gene expression 
induced by this growth factor. Towards this end, we 
carried out a microarray analysis of genes regulated by 
HRG in T-47D breast cancer cells. Cells were treated 
with HRG (20 ng/ml) or vehicle, and 6 h later RNA from 
three replicates was extracted and reverse transcribed to 
cDNA. Gene expression profiling was carried out using 
an Affymetrix GeneChip Human Gene 1.0 ST Array 
(which includes more than 28,000 genes). Using a 1.5-
fold change relative to vehicle-treated cells as a cut-off, 
we found that 1130 genes (represented by 1176 probes) 
were differentially expressed after HRG treatment 
relative to vehicle (p-values < 0.005, fold-change (FC) 
> 1.5). Among the transcripts modulated by HRG in 
T-47D cells, 516 were up-regulated and 614 were down-
regulated (Figure 1A). A complete list of HRG-regulated 
genes is presented in Supplementary Table S1. The top 
20 up- and down-regulated genes are shown in Table 1. 
The highest inductions were for GLIPR1 (~30-fold), a 
gene hormonally-regulated in breast cancer cells [34], 
and SYTL2 (~12-fold), a trafficking protein also known as 
Breast Cancer-Associated antigen SGA-72M [35]. Several 
top up-regulated genes were associated with motility, 
adhesion, invasiveness, and metastasis in breast cancer or 
other cancers, such as GBP1, ITGB6, ITGA2, and matrix 
metalloproteases MMP10 and MMP1.
Functional enrichment analysis for the categorization 
of HRG regulated genes identified “Extracellular matrix 
(ECM) organization/degradation”, “Activation of matrix 
metalloproteinases” and “Regulation of NF-kappa B 
and TNF pathways” as the predominant biofunctions 
associated with gene expression changes (Figure 1B). This 
is consistent with the well-established association of ErbB 
receptors, including ErbB3, with metastatic processes 
as well as with cytokine/pro-inflammatory pathways 
that play important roles in breast cancer progression 
[22, 36, 37]. In addition, we carried out a pathway-based 
representation analysis (PARADIGM) of deregulated 
transcripts, which led to the identification of signaling 
pathways that were specifically activated or inactivated 
by HRG (Figure 1C). One of the pathways identified 
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Table 1: Genes regulated by HRG in T-47D cells
Gene Name Entrez ID Description Fold change
Top twenty HRG up-modulated genes
GLIPR1 11010 GLI pathogenesis-related 1 30.8
SYTL2 54843 Synaptotagmin like 2 12.6
GBP1 2633 Guanylate binding protein 1, interferon-inducible 8.3
ITGB6 3694 Integrin subunit beta 6 6.5
AGPAT9 (GPAT3) 84803 1-acylglycerol-3-phosphate O-acyltransferase 9 5.7
DUSP6 1848 Dual specificity phosphatase 6 5.7
MAP1B 4131 Microtubule associated protein 1B 5.4
MMP10 4319 Matrix metallopeptidase 10 5.3
ANXA1 301 Annexin A1 4.7
LYN 4067 LYN proto-oncogene, Src family tyrosine kinase 4.6
MMP1 4312 Matrix metallopeptidase 1 4.5
SERPINA3 12 Serpin peptidase inhibitor, clade A member 3 4.5
MIR21 406991 MicroRNA 21 4.4
KRTAP3-1 83896 Keratin associated protein 3-1 4.3
SPRR1A 6698 Small proline-rich protein 1A 4.1
SLC16A9 2200963 Solute carrier family 16 member 9 4.1
EPGN 255324 Epithelial mitogen 3.9
ITAG2 3673 Integrin subunit alpha 2 3.9
IL6R 3570 Interleukin 6 receptor 3.9
SERPINB8 5271 Serpin peptidase inhibitor, clade B member 8 3.8
Top twenty HRG down-modulated genes
RANBP3L 202151 RAN binding protein 3-like –6.5
CAB39L 81617 Calcium binding protein 39 like –5.1
ODZ2 (TENM2) 57451 Teneurin transmembrane protein 2 –4.1
C10orf81 (PLEKHS1) 79949 Pleckstrin homology domain containing S1 –3.5
AKAP6 9472 A-kinase anchoring protein 6 –3.5
DLG2 1740 Discs, large homolog 2 –3.5
MDGA2 161357 MAM domain glycosylphosphatidylinositol anchor 2 –3.3
FOXN3 1112 Forkhead box N3 –3.2
KLHL24 54800 Kelch like family member 24 –3.2
NR1D2 9975 Nuclear receptor subfamily 1 group D member 2 –3.1
CDH10 1008 Cadherin 10, type 2 (T2-cadherin) –3.0
ANK3 288 Ankyrin 3, node of Ranvier (ankyrin G) –2.9
LRRC31 79782 Leucine rich repeat containing 31 –2.9
BLNK 29760 B-cell linker –2.9
VEPH1 79674 Ventricular zone expressed PH domain containing 1 –2.8
TMEM229B 161145 Transmembrane protein 229B –2.8
ACOT6 641372 Acyl-CoA thioesterase 6 –2.7
GRIK4 2900 Glutamate receptor, ionotropic, kainate 4 –2.6
ANKFN1 162282 Ankyrin repeat, fibronectin III domain containing 1 –2.6
CREB3L4 148327 cAMP responsive element binding protein 3-like 4 –2.5
The table depicts the top 20 up- and down-regulated genes by HRG in T-47D cells, with the corresponding changes in 
expression.
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with this analysis is the CXCR4 pathway. Notably, we 
reported that HRG-induced activation of P-Rex1/Rac1 
and motility via ErbB3 in breast cancer cells is mediated 
by transactivation of CXCR4 [15], a G-protein-coupled 
receptor widely involved in metastatic dissemination [38]. 
The PARADIGM analysis also revealed the activation of 
PRKCA (PKCα), ITGB6 (integrin β6), LYN, and TAp63g 
pathways. The APOBEC3G complex involved in DNA 
deamination was among the pathways deactivated by 
HRG.
P-Rex1 controls gene expression in breast cancer 
cells
In previous studies we demonstrated that the Rac-
GEF P-Rex1 is overexpressed in luminal breast cancer 
cells. We showed that HRG causes significant activation 
of P-Rex1 in breast cancer cells through activation of 
ErbB3 [15, 39]. Among the multiple Rac-GEFs expressed 
in luminal breast cancer cells, P-Rex1 was found to be 
key for the activation of Rac1 as well as for driving 
cell motility, growth and tumorigenesis downstream of 
ErbB receptors [15]. To assess the potential contribution 
of P-Rex1 in gene expression mediated by HRG, we 
next carried out a microarray analysis in T-47D cells 
subject to P-Rex1 RNAi depletion. As most luminal 
breast cancer cells, T-47D cells express high P-Rex1 
levels [15]. To silence P-Rex1 expression, we used two 
different RNAi duplexes (P-Rex1 #1 and P-Rex1 #2). 
A non-target RNAi duplex (NTC) was used as control. 
There was a significant reduction in P-Rex1 protein and 
mRNA levels upon transfection with either P-Rex1 RNAi 
duplex, as determined by Western blot and qPCR analysis, 
respectively. On the other hand, no significant changes in 
Figure 1: Changes in gene expression induced by HRG in T-47D cells. T-47D cells were treated with HRG (20 ng/ml) or 
vehicle for 6 h. Total RNA from three replicates was extracted and reverse transcribed to cDNA. Gene expression profiling was carried out 
using an Affymetrix GeneChip Human Gene 1.0 ST Array. (A) Heatmap of the microarray data showing changes in gene expression by 
HRG (p-values < 0.005, fold changes (FC) > 1.5). The top 10 up- and down-regulated genes are indicated. (B) Enriched biofunctions of 
HRG-modulated genes, as determined by ClueGO analysis. The percentage of genes per term is proportionally represented in the pie chart. 
(C) PARADIGM inferences of the most variable integrated pathway activities using the normalized gene expression profiles of the HRG 
modulated transcripts.
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P-Rex1 expression could be observed in cells transfected 
with NTC RNAi relative to parental T-47D cells 
(Figure 2A and 2B). In agreement with previous studies 
[15], P-Rex1 RNAi depletion caused a marked reduction 
in HRG-induced activation of Rac1, as determined by 
measuring Rac1-GTP levels using a pull-down assay 
(Figure 2B). 
P-Rex1-regulated genes were defined as those in 
which both P-Rex1 RNAi duplexes caused a statistically 
significant change (p < 0.05) in gene expression compared 
to NTC and parental cells. This analysis revealed a set of 
89 HRG-regulated genes that were sensitive to P-Rex1 
RNAi, as displayed in the heatmap shown in Figure 2C. 
Among these genes, 50 were positively regulated by 
P-Rex1 (i.e., induction by HRG was reduced upon P-Rex1 
silencing) and 39 were negatively regulated by P-Rex1 
(i.e., repression by HRG was reduced upon P-Rex1 
silencing). A complete list of P-Rex1-regulated genes is 
presented in Supplementary Table S2. The top 10 genes 
affected by P-Rex1 RNAi are ranked in Figure 3A and 
3B. Several genes with the largest induction by HRG were 
markedly affected as a consequence of P-Rex1 silencing, 
among them the matrix metalloproteases MMP10 and 
MMP1, GBP1, and GLIPR1. We next carried out a 
functional enrichment analysis to identify biofunctions 
associated with P-Rex1 regulated genes. This analysis 
Figure 2: Depletion of P-Rex1 from T-47D cells using RNAi. T-47D cells were transfected with two different P-Rex1 RNAi 
duplexes (P-Rex #1 and P-Rex #2) or a non-target control RNAi duplex (NTC). After 16 h, cells were serum starved for 48 h and stimulated 
with HRG (20 ng/ml) or vehicle for 5 min. (A) Rac1-GTP levels in response to HRG were determined using a pull-down assay. Upper 
panel, representative experiment. Lower panel, densitometric analysis of Rac1-GTP levels normalized to total Rac1. Data (mean ± S.E.M., 
n = 3) are expressed as fold-change relative to NTC, +HRG. ***p < 0.005. (B) Determination of PREX1 mRNA levels by qPCR. Expression 
was normalized to the housekeeping gene B2M. Data was expressed as fold-change relative to NTC. The experiment was performed in 
triplicate samples. Similar results were obtained in two additional independent experiments. ***p < 0.005. (C) Heatmap of genes regulated 
by HRG that are sensitive to P-Rex1 RNAi depletion. (q < 0.001; FC >1.5). 
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revealed “Extracellular matrix organization”, “Cell 
migration” and “Regulation of chemotaxis” as the most 
significant functions linked to P-Rex1 (Figure 3C).
MMP10 expression is regulated by the P-Rex1/
Rac1 pathway 
In order to validate results from the microarray 
analysis, we chose MMP10, which has been previously 
implicated in metastasis in breast cancer cells as well 
as in other cancer types [40–44]. A qPCR approach 
was developed to assess MMP10 mRNA levels. We 
observed that MMP10 expression could not be detected 
in T-47D cells under basal conditions. Upon HRG 
treatment, a significant elevation in MMP10 expression 
levels was observed. Consistent with data from the 
microarray analysis, the induction of MMP10 by HRG 
was significantly reduced in T-47D cells subject to 
P-Rex1 RNAi depletion (Figure 4A). Similar results were 
observed in SK-BR3 breast cancer cells, which express 
high P-Rex1 levels (Supplementary Figure S1).
Next, we asked if the effects of P-Rex1 on gene 
expression are mediated by Rac. We reasoned that 
impairing the GDP/GTP nucleotide exchange should 
affect MMP10 induction by HRG. To test this hypothesis, 
we ectopically expressed β2-chimaerin, a Rac-specific 
GAP that accelerates GTP hydrolysis from Rac1 leading 
to its inactivation, as extensively demonstrated in cell-free 
systems and cell lines, including T-47D breast cancer cells 
[14, 45]. We infected T-47D cells with the β2-chimaerin 
adenovirus (AdV) at different multiplicities of infection 
(m.o.i. = 1–100 pfu/cell). As a control, we used a LacZ 
AdV [45]. Significant overexpression of β2-chimaerin was 
achieved, particularly at m.o.i. = 100 pfu/cell (Figure 4B). 
As expected, and in agreement with previous reports [14, 
45], expression of β2-chimaerin inhibited Rac1 activation 
by HRG, as judged by the reduction in Rac1-GTP levels. 
At m.o.i. = 100 pfu/cell, which impaired Rac activation 
by 65 %, the β2-chimaerin AdV significantly inhibited 
MMP10 induction (60% reduction compared with LacZ 
AdV at the same m.o.i.) (Figure 4C). Therefore, consistent 
with the requirement of P-Rex1 for MMP10 induction, 
Figure 3: Effect of P-Rex1 RNAi on the expression of genes regulated by HRG. T-47D cells were transfected with two 
different P-Rex1 RNAi sequences (P-Rex #1 and P-Rex #2), or a non-target control RNAi (NTC). After 16 h, cells were serum starved 
for 48 h and stimulated with HRG (20 ng/ml) or vehicle for 6 h. Gene expression profiling was carried out using an Affymetrix GeneChip 
Human Gene 1.0 ST Array. P-Rex1-regulated genes were defined as those in which both P-Rex1 RNAi duplexes (#1 and #2) caused a 
statistically significant change (p < 0.05) in gene expression compared to NTC and parental cells. (A) Effect of P-Rex1 RNAi on genes 
induced by HRG. (B) Effect of P-Rex1 RNAi on genes repressed by HRG. For A and B, results are expressed as % of inhibition by P-Rex1 
RNAi of the induction (for A) or repression (for B) in gene expression caused by HRG. Only the top 10 P-Rex1 regulated genes are shown. 
(C) CluePedia network of functionally enriched pathways and genes modulated by the HRG/P-Rex1 pathway in T-47D cells.
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Figure 4: Induction of MMP10 by HRG is mediated by P-Rex1. (A) T-47D cells were transfected with two different P-Rex1 
RNAi duplexes (P-Rex #1 and P-Rex #2), or a non-target control RNAi duplex (NTC). After 16 h, cells were serum starved for 48 h and 
stimulated with HRG (20 ng/ml) or vehicle for 6 h. MMP10 mRNA levels were determined by qPCR. Expression was normalized to the 
housekeeping gene B2M. Data was expressed as fold-change relative to NTC, +HRG. The experiment was performed in triplicate samples. 
Similar results were obtained in two additional independent experiments. *p < 0.05; **p < 0.01 vs. NTC, +HRG. ND, non detectable. (B) 
Effect of β2-chimaerin on HRG-induced activation of Rac1. T-47D cells were serum starved for 48 h and then infected with AdVs for either 
β2-chimaerin or LacZ (control) using different m.o.i.’s (1–100 pfu/cell). After 16 h, cells were stimulated with either HRG (20 ng/ml) or 
vehicle for 5 min, and Rac1-GTP levels were determined using a pull-down assay. Upper panel, representative experiment. Lower panel, 
densitometric analysis of Rac1-GTP levels normalized to total Rac1. Data (mean ± S.E.M., n = 3) are expressed as fold-change relative to 
cells infected with LacZ AdV (m.o.i. = 1 pfu/cell), + HRG (lower panel). *p < 0.05 vs. LacZ AdV 100 m.o.i., +HRG. (C) MMP10 mRNA 
levels were determined by qPCR in response to HRG (20 ng/ml) or vehicle treatment (6 h). Data was normalized to the housekeeping gene 
B2M, and expressed as fold-change relative to cells infected with LacZ AdV (m.o.i. = 1 pfu/cell), +HRG. The experiment was performed 
in triplicate samples. Similar results were obtained in two additional independent experiments. ***p < 0.005 vs. LacZ AdV 100 m.o.i. + 
HRG. ND, non detectable.
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these results indicate that in breast cancer cells MMP10 
expression is regulated by Rac1 activation. MMP10 could 
also be induced upon activation of the G-protein-coupled 
receptor CXCR4 with SDF-1, which also leads to Rac1 
activation (Supplementary Figure S2).
Correlation of MMP10 and P-Rex1 expression in 
human luminal breast cancer
In order to determine if potential associations 
between P-Rex1 and MMP10 exist in human breast cancer, 
we first performed a comparative analysis of PREX1 
and MMP10 expression in paired breast carcinomas and 
normal tissue, using the TCGA (The Cancer Genome 
Atlas) breast cancer data obtained from the UCSC Xena 
resource (http://xena.ucsc.edu/). Consistent with our 
previous immunohistochemistry and bioinformatics 
analyses [15, 20], RNA-seq expression data revealed 
higher PREX1 levels in luminal breast cancer specimens 
relative to normal samples from the same patients (p = 
7.15e–11, n = 168) (Figure 5A). Similarly, MMP10 levels 
are elevated in luminal breast tumors compared to their 
normal counterparts (p = 2.2e–16) (Figure 5B). Most 
notably, as shown in Figure 5C, there was a significant 
positive correlation between PREX1 and MMP10 levels 
in luminal breast cancer (r = 0.50; p < 0.0001). On the 
other hand, a similar analysis carried out in basal breast 
cancer specimens revealed that PREX1 levels were not 
significantly different (p > 0.05, n = 36) between cancer 
and normal tissue (Figure 5D), which is consistent with 
our previous study [15, 20]. Likewise, expression of 
MMP10 did not differ (p > 0.05) between basal cancer 
and normal samples (Figure 5E). As shown in Figure 5F, 
there was no correlation between PREX1 and MMP10 in 
basal breast cancer (r = 0.28; p > 0.05). Despite the low 
number of samples from HER2 positive patients available 
for this analysis, there were no obvious differences 
in the expression of PREX1 (Figure 5G) and MMP10 
(Figure 5H) in this breast cancer subtype (p > 0.05, 
n = 18), nor a significant correlation between PREX1 and 
MMP10 expression could be found (r = 0.17; p > 0.05) 
(Figure 5I). 
Lastly, to add prognostic value to our studies, we 
asked if MMP10 expression in patients could be linked 
to survival. Luminal A breast cancer patients with high 
PREX1 levels from which follow-up data was available 
were divided into two groups, low MMP10 and high 
MMP10 levels, based on the median expression values. 
As shown in Figure 5J, Kaplan-Meier analysis revealed 
that the subgroup of patients with high MMP10 expression 
was associated with shorter recurrence-free survival 
compared to those with low expression of the MMP10 
gene (p = 0.019). These data suggest that expression of 
MMP10 in luminal tumors may greatly influence patient 
outcome, and that high MMP10 levels are an indicator of 
poor long-term survival.
DISCUSSION
Studies from our group and others reported that 
P-Rex1, a Rac-GEF originally discovered in neutrophils 
[16], is highly expressed in a subset of breast cancers, 
specifically in the luminal subtype, and that its expression 
is associated with the development of breast cancer 
metastasis [15, 19]. The link with metastasis is supported 
by the presence of P-Rex1 positive cancer cells in lymph 
nodes of breast cancer patients [15]. More recent studies 
highlighted important roles for P-Rex1 in invasiveness of 
prostate cancer and melanoma cells [46, 47]. Functional 
studies revealed that P-Rex1 plays essential roles in the 
control of actin cytoskeleton reorganization and breast 
cancer cell motility driven by activation of ErbB receptors. 
In this context, the relevance of ErbB tyrosine-kinase 
receptors in breast cancer is well established. Indeed, 
ErbB2 amplification is a hallmark of human breast cancer, 
and a number of ErbB ligands are highly expressed in 
breast tumors, including the EGFR ligand TGFα and 
the ErbB3/ErbB4 ligand HRG [21, 22, 24, 48, 49]. Both 
ErbB2 overexpression and ErbB3 activation by HRG 
have been linked to breast cancer metastasis [25]. The 
main goal of this study was to identify genes regulated 
by P-Rex1 in the context of HRG stimulation in breast 
cancer cells, with the ultimate goal of establishing effector 
pathways implicated in P-Rex1 function.
In this study, we first focused on the profiling 
analysis of genes regulated by HRG in breast cancer cells. 
As anticipated from the multiplicity of pathways activated 
by ErbB ligands, HRG stimulation of T-47D breast cancer 
cells led to marked changes in gene expression, both 
leading to up- and down-regulation. It is not surprising 
that HRG-regulated genes include many associated with 
extracellular matrix reorganization/degradation and 
cytokine function, which is consistent with the well-
established roles of HRG in conferring an invasive and 
pro-metastatic phenotype. Pathway-based representation 
analysis using PARADIGM revealed the activation of 
pathways known to be associated with ErbB receptor 
function and breast cancer progression, such as ITGB6. 
The ITGB6 gene, coding for the integrin subunit β6, has 
been associated with metastasis to distant sites and poor 
prognosis in breast cancer patients, and targeting avβ6 
integrin has been proposed as a novel therapeutic approach 
for treating high-risk and trastuzumab-resistant breast 
cancer patients [50]. A second interesting finding relates 
to the identification of the PRKCA (PKCα) pathway as a 
HRG effector. PKCα has been functionally associated with 
ErbB2, the main dimerization partner for ErbB3, and was 
found to be an essential mediator of ErbB2-driven breast 
cancer invasiveness [51, 52]. The PARADIGM analysis 
also identified the CXCR4 pathway as activated by HRG. 
In our previous study [15], we established that HRG-
induced activation of P-Rex1/Rac1 and motility in luminal 
breast cancer cells is mediated by transactivation of 
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Figure 5: Expression of PREX1 and MMP10 in different breast cancer subtypes. Comparison of PREX1 and MMP10 
expression in paired breast carcinomas and normal tissues according to subtype was carried out using the TCGA breast cancer data obtained 
from the Xena resource. (A, D, and G) Expression of PREX1 in luminal, basal, and HER2 positive breast cancer. (B, E, and H) Expression 
of MMP10 in luminal, basal, and HER2 positive breast cancer. (C, F, and I) Correlation between PREX1 and MMP10 expression in 
luminal, basal, and HER2 positive breast cancer. (J) Kaplan-Meier curve analysis for P-Rex1 positive cases according to low and high 
MMP10 expression.
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CXCR4, a G-protein-coupled receptor widely associated 
with breast cancer cell metastatic dissemination. Indeed, 
HRG treatment promotes the phosphorylation and 
activation of CXCR4, leading to the release of Gbγ 
subunits from heterotrimeric Gi proteins that are required, 
in conjunction with PI3K stimulation, to activate P-Rex1/
Rac1 and confer a motile response [17]. It is important to 
note that a previous microarray analysis by Amin et al. 
[28] characterized HRG-regulated genes in T-47D cells, 
although this study focused primarily on immediate early 
genes that in most cases do not overlap with our analysis. 
The differences may relate to the fact that our study 
involved a longer HRG treatment (6 h), as we aimed to 
recapitulate a chronic growth factor stimulation scenario 
that occurs in human breast tumors.
The identification of P-Rex1 regulated genes in 
breast cancer is also a notable finding. We identified 
a subset of 89 HRG-modulated genes sensitive to 
P-Rex1 RNAi depletion. Although functional studies to 
characterize the role of these specific genes in the HRG/
P-Rex1 pathway are beyond the scope of the current 
study, the biofunctions associated with P-Rex1, which 
we identified through functional enrichment analysis, 
emphasize the relevance of the pathway in cell migration, 
regulation of chemotaxis, and extracellular matrix 
organization. Previous studies in neutrophils established 
that P-Rex1 serves as a regulator of chemotaxis in 
response to a variety of extracellular stimuli [53]. In 
addition, studies in various cancer cell lines, including 
breast cancer cells, established key roles for P-Rex1 in 
cell migration stimulated by growth factors such as HRG 
as well as GPCR ligands such as SDF-1, a chemokine that 
activates CXCR4 [15, 19, 54]. Silencing P-Rex1 from 
breast cancer cells impairs HRG-induced cytoskeleton 
reorganization and ruffle formation, processes that are 
key for cellular motility [15]. Emerging evidence in a 
number of cancer types indicates that P-Rex1 is involved 
in metastatic dissemination. The first evidence was found 
using prostate cancer cell xenografts, where expression 
of P-Rex1, but not a GEF dead P-Rex1 mutant, induced 
lymph node metastasis [46]. In addition, P-Rex1 knockout 
mice are resistant to metastasis when crossed to a murine 
model of melanoma [47]. Expression of P-Rex1 also 
promotes an invasive behavior in human fibroblasts 
[55]. The involvement of P-Rex1 in breast cancer 
invasiveness is still poorly understood, probably due to the 
limited availability of invasive luminal cellular models; 
nevertheless P-Rex1 expression has been associated with 
a higher probability of developing metastasis, and P-Rex1 
positive cells can be readily detected in lymph nodes of 
breast cancer patients [15]. In this context, our microarray 
analysis identified a number of gene products associated 
with the remodeling of the extracellular matrix, among 
them MMP10. Although MMP10 has been less studied 
compared to other MMPs, its expression has been shown 
in human specimens of luminal A breast tumors [56]. 
Moreover, a role for MMP10 has been proposed in MCF-
7 breast cancer cells via regulation of the BAD protein 
[40]. Interestingly, a recent study established that MMP10 
contributes to hepatocarcinogenesis driven by CXCR4 
stimulation [41]. Our results showing that SDF-1 activate 
Rac1 and induce MMP10 in breast cancer cells are in line 
with this finding. A role for MMP10 downstream of ErbB2 
has been also demonstrated in pancreatic adenocarcinoma 
[42]. In addition, MMP10 has been implicated in lung 
cancer initiation driven by oncogenic K-Ras [44, 57]. 
Although the detailed mechanisms by which P-Rex1/Rac1 
controls MMP10 expression are not known, we speculate 
that the effect may be mediated by the ERK pathway. 
Indeed, ERK has been shown to be a downstream effector 
of P-Rex1 in breast cancer cells and mediates MMP10 
induction in other cell types [41, 58, 59]. Future studies in 
our laboratory are aimed at dissecting potential roles for 
MMP10 and other relevant genes identified in our analysis 
in breast cancer progression. It is also interesting that our 
Kaplan-Meier analysis revealed a shorter recurrence-
free survival in high PREX1 patients with high MMP10 
expression relative to those with low MMP10 expression, 
indicating that MMP10 expression can greatly influence 
patient outcome. The significant association between 
PREX1 and MMP10 expression in luminal tumors, 
together with the poor prognosis found in luminal breast 
cancer patients with high PREX1 and MMP10 expression, 
suggest a causal relationship with disease progression that 
deserves to be fully explored.
In summary, we identified the P-Rex1/Rac1 pathway 
as a regulator of the expression of genes in luminal breast 
cancer. One attractive possibility is that actin cytoskeleton 
reorganization, which is tightly regulated by P-Rex1/Rac1, 
contributes to the observed expression in genes. Indeed, 
there is extensive evidence that gene expression is tightly 
controlled by actin cytoskeleton dynamics [60]. Our 
studies emphasize the complexities of Rac-GEF effector 
mechanisms in cancer and suggest that phenotypes driven 
by this pathway may involve the regulation of genes 
implicated in various aspects of cell motility, invasiveness 
and extracellular matrix remodeling.
MATERIALS AND METHODS
Cell culture and reagents
T-47D and SK-BR3 cells were obtained from ATCC 
(Manassas, VA) and were grown in DMEM medium 
(Lonza; Basel, Switzerland) supplemented with 10% FBS 
(Hyclone; Logan, UT). Heregulin β1 and SDF-1 were 
obtained from R&D (Minneapolis, MN).
RNAi transfection and adenoviral infection 
For transient depletion of P-Rex1, we used ON-
TARGETplus siRNAs J-010063-11 (#1) and J-010063-
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12 (#2), or siRNA pool L-010063-01-0005 (Dharmacon; 
Lafayette, CO). ON-TARGETplus non-targeting siRNA 
(D-001810-01) or non-targeting siRNA pool (D-001810-
10) were used as controls (NTC). RNAi duplexes 
were transfected into T-47D cells using Lipofectamine 
RNAiMAX (Invitrogen; Carlsbad, CA) following the 
instructions provided by the manufacturer. After 16 h, cells 
were serum starved, and 48 h later subject to HRG treatment.
For adenoviral infections, T-47D cells were 
serum starved for 32 h, and then infected with different 
multiplicities of infections (m.o.i.) of either β2-chimaerin 
or LacZ (control) AdV, as in previous studies [45, 61]. 
Experiments were carried out 16 h after adenoviral 
infection.
Rac1-GTP pull-down and Western blot assays
After serum starvation for 48 h, cells were 
stimulated with HRG (20 ng/ml) or SDF-1 (100 ng/ml) 
for 5 min. Rac1-GTP levels were determined with a pull-
down assay using the p21-binding domain (PBD) of Pak1, 
as described previously [62]. Briefly, cells were lysed in a 
buffer containing 20 mM Tris-HCl, pH 7.4, 150 µM NaCl, 
5 mM MgCl2, 0.5% NP40, 5 mM β-glycerophosphate, 1 
mM DTT, protease inhibitors, and 10 mg/ml GST-PBD. 
Lysates were cleared by centrifugation (10 min at 4ºC, 
13,000 × g) and incubated with glutathione-Sepharose 4B 
beads (GE Healthcare, Mickleton, NJ) for 45 min at 4ºC. 
After centrifugation, the beads were washed twice with the 
pull-down buffer and run on SDS-PAGE gels.
For Western blot analysis, the following antibodies 
were used: anti-Rac1 (Upstate Biotechnology; Lake 
Placid, NY), anti-P-Rex1 and anti-vinculin (Sigma-
Aldrich; St. Louis, MO). Bands were visualized by 
Enhanced Chemiluminescence (ECL). Images were 
captured using an Odyssey Fc system (Li-Cor Biosciences; 
Lincoln, NE). Image processing and densitometry analysis 
were carried out using the Image Studio Lite software (Li-
Cor Biosciences).
Microarray data processing, statistical and data 
mining analysis 
For gene expression analysis, T-47D cells were 
serum starved and then stimulated with HRG (20 ng/ml) 
or vehicle (PBS) for 6 h in 60-mm plates. Three biological 
replicates for each experimental condition were used. 
For the analysis of P-Rex1-regulated genes, parental, 
NTC, P-Rex1#1 and P-Rex1#2 T-47D cells, with and 
without HRG treatment, were used (24 samples). Total 
RNA for each sample was obtained using the miRNeasy 
kit (Qiagen; Valencia, CA), reversed transcribed to 
cDNA (GeneChip® Whole Transcript cDNA Synthesis 
and Amplification Kit, Affymetrix; Santa Clara, CA), 
fragmented, and end labeled (GeneChip® WT Terminal 
Labelling Kit, Affymetrix) for further hybridization to 
an Affymetrix GeneChip Human Gene 1.0 ST Array 
(GPL6244) according to the standard protocols at the 
University of Pennsylvania Molecular Profiling Facility. 
RNA quality was analyzed using the Agilent Bioanalyzer 
Nano assay. We carried out QC and normalization 
procedures in R/Bioconductor using the “simpleaffy” 
package [63]. The Robust Multichip Average algorithm 
was employed for background adjustment, quantile 
normalization and probe set values summarization [64].
To compare T-47D parental (no RNAi) and NTC 
RNAi groups vs. P-Rex1 RNAi #1 and P-Rex1 RNAi 
#2, with and without HRG treatment, we utilized the 
Rank Products test [65]. Statistical analysis and heatmap 
visualization of differentially expressed transcripts were 
done with the MultiExperiment Viewer software (MeV 
4.9) [66]. The complete microarray data are available in 
the Gene Expression Omnibus database (GSE77974). 
We used ClueGO and CluePedia Cytoscape›s plug-in 
for functional enrichment analysis, network generation 
and visualization of the gene expression changes [67]. In 
addition, InnateDB resource (http://www.innatedb.com/) 
was employed for over representation analysis of GO 
terms based on the list of deregulated genes. 
Pathway-based analysis was performed using the 
PARADIGM software [68] at the Five3 Genomics server 
(default options; discretization bounds of 33%) on the 
basis of the normalized gene expression profiles of the 
deregulated transcripts associated with HRG treatment in 
T-47D parental cells. PARADIGM produces a data matrix 
of integrated pathway activities (IPA). This data matrix 
was used in place of the mRNA expression profiles to 
identify the topmost variable IPAs among groups.
Real-time quantitative PCR (qPCR)
Total RNA from cells was isolated using the 
RNeasy Mini Kit (Qiagen). One μg of total RNA was 
reverse transcribed to cDNA with the TaqMan Reverse 
Transcription Kit (Invitrogen). qPCR was performed 
in a ABI PRISM 7700 detection system using TaqMan 
Universal PCR MasterMix (Applied Biosystems, 
Branchburg, NJ), target primers (45 nM), fluorescent 
probe (12.5 nM) and the cDNA. TaqMan probes specific 
for PREX1, MMP10 and the housekeeping gene B2M 
(used for normalization) were purchased from Applied 
Biosystems. PCR product formation was continuously 
monitored using the Sequence Detection System software 
version 1.7. Results were expressed as fold-change of the 
target gene by 2-ΔΔCt and normalized to the NTC sample. 
All qPCR reactions were performed in triplicate. Every 
experiment was performed three times.
In silico analysis of PREX1 and MMP10 
expression in breast carcinomas
Comparative analysis of PREX1 and MMP10 mRNA 
expression in human breast samples was done in paired 
breast carcinomas and normal tissue, using the TCGA 
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breast cancer data obtained from the UCSC Xena resource 
(http://xena.ucsc.edu/). PREX1 and MMP10 RNA-seq 
expression profiles were compared in normal and tumor 
sample using a paired t-test. Correlation analysis between 
both genes among normal and breast cancer samples was 
done with a Pearson’s test.
Prognostic value of PREX1 and MMP10 profiles 
was evaluated in a subset of breast cancer patients with 
follow-up data. Patients with primary invasive breast 
carcinomas were divided into two groups (high PREX1/
low MMP10 and high PREX1/high MMP10) based on the 
median gene expression values. These groups were then 
compared for recurrence free survival using the Survival 
R package. 
Additional statistical analysis
Statistical analysis of qPCR data (-∆∆Ct values) and 
densitometry data from Rac1-GTP pull-down assays were 
done by ANOVA and Bonferroni’s multiple comparison 
tests, using the GraphPad Prism software.
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